FinnCure: Next-Gen
VLP Technology
Next-gen broad spectrum therapy. Virus-like particles for treating
and preventing pathogenic and non-pathogenic diseases.
Smart Particles.
Safer Tomorrow.
Designing safe, and adaptable VLPs for diverse medical applications - from disease prevention and immunotherapy to targeted drug delivery.
Delivering the Future of Targeted Medicine
We develop a novel technology platform for creating synthetic virus-like particles that mimic viral behavior without using actual viruses. These particles:
Carry therapeutic compounds
Our platform supports fast customization, making it suitable for both existing treatments and future health threats.
BREAKTROUGH VALIDATION OF VLP TECHNOLOGY
Targeted Delivery. Real Results.
Safe, effective, and fast-acting--our VLPs protect cells and deliver therapies precisely where needed.
virus blocking
Virus blocking efficacy validated for at least 6 hours by Tebu-Bio Finance
cell viability
Non-toxic even at extremly large doses
(hundreds of µg/ml)
Engineered for Impact
Our proprietary particles demonstrate exceptional safety, precision targeting, and antiviral efficacy - validated trough independent testing and real-world conditions.
Smart Particles.
Real Impact.
VLPs designed for real-world application
and therapeutic flexibility.
Careers
Join Us in
Revolutionizing
Healthcare.
Job Position 1
Job Position 2
